Adaptimmune Therapeutics Plc Overview
Get informed when a big investor buys or sells
+ Follow-0.10
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for ADAP is -0.1. That is below the Healthcare sector average of 21.65. Investors often review this figure alongside Adaptimmune Therapeutics Plc's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ADAP currently prints -0.1 for P/E ratio, while the sector average sits near 21.65. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at Adaptimmune Therapeutics Plc's growth, margins, and balance sheet.
A P/E ratio of -0.1 for Adaptimmune Therapeutics Plc is not 'good' or 'bad' on its own. Compare it with the peer average (21.65) and with ADAP's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ADAP's P/E ratio (-0.1), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Adaptimmune Therapeutics Plc's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
